Abstract: Engineered proteins, polynucleotides encoding such proteins, and methods of use thereof are provided, which engineered proteins enhance the sensitivity of a cell to IL-2.
Type:
Grant
Filed:
December 5, 2018
Date of Patent:
October 10, 2023
Assignees:
The Board of Trustees of the Leland Stanford Junior University, Parker Institute for Cancer Immunotherapy
Inventors:
Kenan Christopher Garcia, Sean Parker, Jonathan Sockolosky, Michael Hollander
Abstract: The present invention relates, inter alia, to compositions and methods, including heterodimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity.
Type:
Grant
Filed:
March 24, 2021
Date of Patent:
October 10, 2023
Assignee:
Shattuck Labs, Inc.
Inventors:
Taylor Schreiber, George Fromm, Suresh De Silva
Abstract: For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.
Type:
Grant
Filed:
May 28, 2021
Date of Patent:
October 10, 2023
Assignees:
Chugai Seiyaku Kabushiki Kaisha, Jichi Medical University, National Institutes of Biomedical Innovation, Health and Nutrition
Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
Type:
Grant
Filed:
October 1, 2020
Date of Patent:
October 10, 2023
Assignee:
Agency for Science, Technology and Research
Abstract: The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express IL1RAP. A related aspect of the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting pathological cells associated with a solid tumour, wherein the cells express IL1RAP. Further provided are pharmacological compositions comprising the agents of the invention and methods of using the same.
Abstract: The problem to be solved is to provide a humanized anti-IL-6 receptor antibody AMA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
Type:
Grant
Filed:
January 31, 2023
Date of Patent:
September 26, 2023
Assignees:
CHUGAI SEIYAKU KABUSHIKI KAISHA, HOFFMANN-LA ROCHE INC.
Inventors:
Toshiyuki Morichika, Daisuke Kameoka, Yoshimi Imaeda, Terutoshi Maeda, Oliver Boris Stauch
Abstract: The present invention relates to changes in interleukin-2 alpha receptors and interleukin-2 analogs with increased binding affinity for interleukin-2 beta receptors.
Type:
Grant
Filed:
March 31, 2021
Date of Patent:
September 5, 2023
Assignee:
HANMI PHARM. CO., LTD.
Inventors:
Euh Lim Oh, Sang Yun Kim, Yong Ho Heo, Jin Young Kim, Cho Rong Park, Jun Sub Park, Hyun Soo Ryu
Abstract: The present invention relates to methods of designing kinase mutants for reprogramming the sensitivity of a target kinase to some specific inhibitors, methods of reprogramming the sensitivity of a target kinase to some specific inhibitors, wherein those kinase inhibitors have little or no affinity for the wild-type target kinase, vectors or cells expressing said mutated kinases, composition and uses thereof for the prevention and/or treatment of a disease or disorder, in particular cancer.
Type:
Grant
Filed:
May 24, 2018
Date of Patent:
August 29, 2023
Assignees:
SIB Swiss Institute of Bioinformatics, CHUV—Centre Hospitalier Universitaire Vaudois, Université de Lausanne, Ludwig Institute for Cancer Research Ltd
Inventors:
Olivier Michielin, Vincent Zoete, George Coukos, Melita Irving, Nahzli Dilek, Patrick Reichenbach, Kelly Ascencao
Abstract: The present disclosure relates to methods that include the use of a first multi-chain chimeric polypeptide and a second multi-chain chimeric polypeptide for stimulating the NK cells, inducing or increasing proliferation of the NK cells, inducing differentiation of the NK cells, and treating a subject in need thereof using activated NK cells.
Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
Type:
Grant
Filed:
April 26, 2021
Date of Patent:
August 22, 2023
Assignee:
The USA, as represented by the Secretary, Dept. of Health and Human Services
Abstract: An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R? polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.
Type:
Grant
Filed:
December 21, 2020
Date of Patent:
August 8, 2023
Inventors:
Xiangdong Qu, Xin Ye, Qiyue Hu, Dongbing Cui, Weikang Tao, Lianshan Zhang, Piaoyang Sun
Abstract: IL33 antagonists alone or in combination with IL-4R antagonists can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in a subject having one or more risk alleles in the intronic IL1RL1 variant rs1420101, in the IL33 variant rs1342326, in both, or in variants in linkage disequilibrium thereof.
Abstract: The present invention is directed to antigen binding proteins and in particular to IL-1? antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
Type:
Grant
Filed:
January 15, 2021
Date of Patent:
July 18, 2023
Assignee:
Agency for Science, Technology and Research
Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.
Abstract: The present invention relates to a heterodimeric Fc-fused protein comprising a first Fc region and a second Fc region of an immunoglobulin Fc pair and a physiologically active protein composed of two or more different subunits, wherein one or more subunits of the physiologically active protein are linked separately to one or more ends of the N-terminus or C-terminus of the first Fc region and/or the second Fc region, and CH3 domains of the first Fc region and the second Fc region are mutated so as to promote the heterodimeric Fc formation. Moreover, the present invention relates to a pharmaceutical composition comprising the heterodimeric Fc-fused protein.
Type:
Grant
Filed:
May 28, 2020
Date of Patent:
July 4, 2023
Assignee:
Ajou University Industry-Academic Cooperation Foundation
Inventors:
Yong Sung Kim, Keunok Jung, Ji Hee Ha, Dong Ki Choi, Hye Ji Choi, Ye Jin Kim
Abstract: The present disclosure provides T-cell modulatory multimeric polypeptides (T-Cell-MMP) and their epitope conjugates comprising at least one immunomodulatory polypeptide (“MOD”) that may be selected to exhibit reduced binding affinity to a cognate co-immunomodulatory polypeptide (“Co-MOD”). The epitope may be, for example, a cancer-associated epitope, an infectious disease-associated epitope, or a self-epitope. The T-Cell-MMP-epitope conjugates are useful for modulating the activity of a T-cell by delivering immunomodulatory peptides, such as IL-2 or IL-2 variants that exhibit reduced binding affinity for the IL-2R, to T-cells in an epitope selective/specific manner, and accordingly, for treating individuals with a cancer, infectious disease or autoimmune disorder.
Type:
Grant
Filed:
April 16, 2022
Date of Patent:
July 4, 2023
Assignee:
Cue Biopharma, Inc.
Inventors:
Ronald D. Seidel, III, Rodolfo J. Chaparro, John F. Ross, Chee Meng Low
Abstract: Provided herein are a fusion protein comprising first and second cytokine domains, and a half-life extension domain; and a pharmaceutical composition thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
Type:
Grant
Filed:
November 19, 2020
Date of Patent:
July 4, 2023
Assignee:
Anwita Biosciences, Inc.
Inventors:
Ziyang Zhong, Fan Ye, Matthew Siegel, Jianing Huang
Abstract: Postoperative adhesion formation at an invasion site and migration of neutrophils to the site of surgical invasion are suppressed by administering an anti-IL-6 receptor antibody and/or a neutrophil-neutralizing antibody.
Type:
Grant
Filed:
October 19, 2018
Date of Patent:
July 4, 2023
Assignees:
Hyogo College of Medicine, Chugai Seiyaku Kabushiki Kaisha